Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis

Annals of the Rheumatic Diseases

Volumn 70, Issue 11, 2011, Pages 1895-1904

  Mariette, Xavier ^a   Matucci Cerinic, Marco ^b   Pavelka, Karel ^c   Taylor, Peter ^d   Van Vollenhoven, Ronald ^e   Heatley, Rebecca ^f   Walsh, Claire ^f   Lawson, Richard ^f   Reynolds, Alan ^g   Emery, Paul ^h  

^a INSERM   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CHARLES UNIVERSITY   (Czech Republic)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e KAROLINSKA INSTITUTE   (Sweden)

^f Complete Market Access ^*  (United Kingdom)

^g Reynolds Clinical Sciences   (United Kingdom)

^h UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CANCER RECURRENCE; CANCER RISK; CLINICAL PRACTICE; DISEASE REGISTRY; HIGH RISK PATIENT; HUMAN; LYMPHOMA; MELANOMA; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SKIN CANCER; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS; EPIDEMIOLOGIC METHODS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; NEOPLASMS; REGISTRIES; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80053565309     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.149419     Document Type: Article

References (51)

1. Smitten AL, Simon TA, Hochberg MC, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.
2. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 2003;14:185-91. (Pubitemid 36693140)
3. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45. (Pubitemid 32173595)
4. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
5. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79.
6. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
7. Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009;68:1177-83.
8. Silman A, Klareskog L, Breedveld F, et al. Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds. Ann Rheum Dis 2000;59:419-20. (Pubitemid 30395597)
9. Geborek P, Saxne T. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:1159-61.
10. Centre for Reviews and Dissemination. Systematic Reviews. CRD's Guidance for Undertaking Reviews in Health Care. York: CRD, University of York, 2009.
11. Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010;69:70-81.
12. Wells GA, Shea B, O'Connell D, et al. http://www.ohri.ca/programs/ clinical-epidemiology/oxford.asp (accessed 26 June 2009).
13. Jüni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282:1054-60. (Pubitemid 29436453)
14. Du Pan SM, Dehler S, Ciurea A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8.
15. Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180-9.
16. Dixon WG, Watson KD, Lunt M, et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010;62:755-63.
17. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
18. Gibofsky A, Palmer W, Keystone EC, et al. Safety profiles of disease-modifying anti-rheumatic drugs and biologics in patients with rheumatoid arthritis: observations from the RADIUS registry (abstract). Arthritis Rheum 2009;60(Suppl 10):1593.
19. Greenberg J, Strand V, Keystone E, et al. TNF inhibitors (TNF-I) and risk of malignancy in 8,072 RA patients followed over 15,495 patient years (Abstract 282). American College of Rheumatology Annual Meeting, 2007.
20. Abasolo L, Carmona L, Gómez-Reino JJ. Is the exposure to TNF antagonists a risk factor for cancer in rheumatoid arthritis? (Abstract 1266). American College of Rheumatology Scientific Meeting, 2008.
21. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-51. (Pubitemid 38725085)
22. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9. (Pubitemid 46764070)
23. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68:648-53.
24. Pallavicini FB, Caporali R, Sarzi-Puttini P, et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 2010;9:175-80.
25. Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010;69:400-8.
26. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6. (Pubitemid 41623851)
27. Askling J. No increase in overall risk for cancer in RA treated with TNF-antagonists, but risks for certain cancer types may be elevated. Ann Rheum Dis 2007;66:54.
28. Askling J. Anti-TNF therapy and risk of skin cancer, data from the Swedish ARTIS registry 1998-2006. Ann Rheum Dis 2009;68:423.
29. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130-5. (Pubitemid 41587856)
30. Mercer LK, Galloway JB, Lunt M, et al. The influence of anti-TNF therapy upon incidence of non-melanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA): results from the BSR Biologics Register (BSRBR) (abstract). Arthritis Rheum 2009;60(Suppl 10):2062.
31. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95. (Pubitemid 47502734)
32. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
33. Symmons DP, Silman AJ. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum 2004;50:1703-6. (Pubitemid 38725080)
34. Dixon W, Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al Arthritis Res Ther 2006;8:111.
35. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52.
36. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
37. Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119-30.
38. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2757-64. (Pubitemid 44497754)
39. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008;372:2152-61.
40. Hudson M, Suissa S. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:805-10.
41. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20. (Pubitemid 41623850)
42. Carmona L, Gómez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8:R72.
43. Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66:880-5. (Pubitemid 46999787)
44. Feltelius N, Fored CM, Blomqvist P, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52. (Pubitemid 40193621)
45. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
46. Geborek P, Bladström A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703. (Pubitemid 40559295)
47. Hetland ML, Unkerskov J, Ravn T, et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scand J Rheumatol 2005;34:40-4. (Pubitemid 40445057)
48. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009;36:898-906.
49. Kristensen L, Saxne T, Geborek P. Serious adverse events during first anti-TNF treatment course in rheumatoid arthritis patients. Ann Rheum Dis 2005;64:430.
50. Kristensen LE, Gülfe A, Saxne T, et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364-9. (Pubitemid 351281272)
51. Watson KD, Dixon WG, Hyrich KL, et al. Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): results from the BSR biologics register. Ann Rheum Dis 2006;65:512.